Guyasuta Investment Advisors Inc. Has $37.69 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Guyasuta Investment Advisors Inc. cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 154,577 shares of the medical instruments supplier’s stock after selling 637 shares during the quarter. Becton, Dickinson and Company comprises 2.5% of Guyasuta Investment Advisors Inc.’s investment portfolio, making the stock its 13th largest holding. Guyasuta Investment Advisors Inc. owned approximately 0.05% of Becton, Dickinson and Company worth $37,691,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BDX. Addenda Capital Inc. increased its position in shares of Becton, Dickinson and Company by 31.3% during the first quarter. Addenda Capital Inc. now owns 30,123 shares of the medical instruments supplier’s stock valued at $7,454,000 after purchasing an additional 7,178 shares during the period. Capital Asset Advisory Services LLC increased its position in shares of Becton, Dickinson and Company by 45.2% during the first quarter. Capital Asset Advisory Services LLC now owns 1,484 shares of the medical instruments supplier’s stock valued at $365,000 after purchasing an additional 462 shares during the period. Indiana Trust & Investment Management CO increased its position in shares of Becton, Dickinson and Company by 126.9% during the first quarter. Indiana Trust & Investment Management CO now owns 236 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 132 shares during the period. Fifth Third Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $542,000. Finally, Procyon Advisors LLC grew its position in Becton, Dickinson and Company by 14.2% in the first quarter. Procyon Advisors LLC now owns 15,396 shares of the medical instruments supplier’s stock valued at $3,810,000 after acquiring an additional 1,912 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the completion of the transaction, the executive vice president now directly owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold 8,615 shares of company stock valued at $2,033,381 over the last 90 days. 0.31% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on BDX. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Barclays upped their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $2.77 on Friday, reaching $233.71. The company’s stock had a trading volume of 2,100,394 shares, compared to its average volume of 1,453,708. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a twelve month low of $224.00 and a twelve month high of $287.32. The company has a market cap of $67.54 billion, a price-to-earnings ratio of 51.48, a PEG ratio of 2.03 and a beta of 0.44. The business’s fifty day moving average price is $234.36 and its 200 day moving average price is $237.84.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the firm posted $2.86 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.